CLASS II Device recall · Reported 1 Mar 2017 · FDA Enforcement Report

HLC-723G8 Analyzer for HbA1c testing recalled by Tosoh Bioscience

Tosoh Bioscience is recalling Tosoh Bioscience HLC-723G8 Analyzer for HbA1c testing, distributed in 48 states. The recall was initiated on 7 Nov 2016 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesAll active analyzers
Quantity recalled682 analyzers

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1225-2017
FDA event ID
75727
Recalling firm
Tosoh Bioscience, South San Francisco, CA
Classification
Class II
Status
Terminated
Recall initiated
7 Nov 2016
FDA classified
17 Feb 2017
Reported
1 Mar 2017
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Device Malfunction

Timeline

7 Nov 2016Recall initiated by company
17 Feb 2017Classified by FDA+102 days
1 Mar 2017Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The device defect associated with this recall may result in HbA1c values with a negative bias in patients with the hemoglobin variants C, D, E and S. The negative bias occurs at the higher levels of HbA1c, e.g. 9%, but not at the diagnostic medical decision point of 6.5%.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

Tosoh Bioscience HLC-723G8 Analyzer for HbA1c testing.

Where it was distributed

Worldwide distribution. The products were shipped to the following states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IL IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, AND WY. The recalled products were shipped to the following countries: Brazil, Chile, Columbia, Guatemala, Costa Rica, Dominican Republic, Eduador, Nicaragua, Panama, Peru, Puerto Rico, Uruguay,

AlaskaAlabamaArkansasArizonaCaliforniaColoradoConnecticutDelawareFloridaGeorgiaIowaIdahoIllinoisKansasKentuckyLouisianaMassachusettsMarylandMaineMichigan

Questions about this recall

Is HLC-723G8 Analyzer for HbA1c testing recalled?

Yes. Tosoh Bioscience recalled HLC-723G8 Analyzer for HbA1c testing on 7 Nov 2016. The recall is Class II and its status is Terminated. Recall number Z-1225-2017.

Why was it recalled?

The device defect associated with this recall may result in HbA1c values with a negative bias in patients with the hemoglobin variants C, D, E and S. The negative bias occurs at the higher levels of HbA1c, e.g. 9%, but not at the diagnostic medical decision point of 6.5%.

Which lots are affected?

All active analyzers

Where was it sold?

Worldwide distribution. The products were shipped to the following states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IL IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, AND WY. The recalled products were shipped to the following countries: Brazil, Chile, Columbia, Guatemala, Costa Rica, Dominican Republic, Eduador, Nicaragua, Panama, Peru, Puerto Rico, Uruguay,

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Tosoh Bioscience

All 74

Other Test Kits & Diagnostics recalls

All 2,656